Rigor-led Discovery
Welcome to the science behind Masinova’s therapeutic development. Our rigor-led, Quality-by-Design (QbD) approach is built to generate reproducible, safety-informed data and advance programs efficiently from preclinical development toward Phase I. Our HIV program is guided by a defined Target Product Profile (TPP), and we are progressing early-stage oncology programs in development. We welcome partners and investors to engage with us—additional program details are available under NDA.
Our Scientific Approach
At Masinova, our scientific approach is built on two core pillars: rigorous research methodologies and Quality-by-Design (QbD) principles. This combination ensures that our HIV and cancer therapies are not only effective but also consistently reproducible, safety-focused, and designed for efficient progression from preclinical stages to Phase I clinical trials.
Reproducibility
We ensure our research is reproducible, minimizing risks and accelerating development timelines.
Safety-Informed
Our therapies are designed with an emphasis on safety, integrating early screens to optimize therapeutic windows.
Efficient Translation
Our QbD approach streamlines the journey from discovery to preclinical milestones, setting the stage for successful clinical trials.
Partner-Ready Preclinical Package
Masinova has built a complete, QbD-driven preclinical package for our lead HIV/oncology program. This package links a clear Target Product Profile (TPP) to qualified assays, defined go/no-go criteria, and an IND-enabling plan. Potential partners can confidently evaluate our assets under NDA.
Comprehensive Data Package
Our comprehensive data package provides potential partners with the insights needed to make informed decisions. This includes detailed reports, assay qualifications, and clear milestones for advancement.
Request Confidential Overview
Interested in learning more about our HIV and cancer therapy programs? Contact us to request a confidential overview under NDA and explore potential partnership or investment opportunities.
